University of Dundee
Dundee, dd1 3sy, United Kingdom
NCT Number: NCT00512057
Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriograms) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge to the treating physician. Evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has been recently strengthened by the finding that basal superoxide production predicts future cardiovascular events in this patient group. The investigators have recently shown that high-dose allopurinol abolishes vascular oxidative stress and improves endothelial function in patients with chronic heart failure, which makes allopurinol a prime candidate to reduce oxidative stress in syndrome X. The hypothesis to be tested in this study is whether allopurinol offers dual benefits of improving vascular function and reducing myocardial ischaemia in patients with cardiac syndrome X. This study may discover a novel way to improve endothelial function and anginal symptoms which are often debilitating in these patients.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Dundee, dd1 3sy, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
allopurinol 300mg twice a day
placebo
Time frame: 3-5 years
Time frame: 3- 5years
University of Dundee
Other
Acronym: APEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02307214
Angina Pectoris, Cardiomyopathies
Bellinzona, Canton Ticino, Switzerland
View Trial DetailsNCT00001459
Angina Pectoris, Aortic Stenosis, Subvalvular
Bethesda, Maryland, United States
View Trial DetailsNCT06212466
Angina, Angina Pectoris
Gainesville, Florida, United States
View Trial DetailsNCT04554004
Angina Pectoris, Arterial Occlusive Diseases
Hanzhou, Zhejiang, China
View Trial Details